Early data presented at the European Society of Medical Oncology (ESMO) 2020 virtual annual meeting from the ongoing phase III IPATential150 study (NCT03072238) showed similar promising responses in PTEN-deficient prostate cancer using the same treatment combination (with the addition of prednisone to the abiraterone arm). Here, PTEN is linked to prostate cancer.